Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House Patent Reform Bill: Battle Looms Over Patent Reexamination Provisions

This article was originally published in The Gray Sheet

Executive Summary

The six-year battle over patent reform legislation is not yet over as the device and drug industries and other leading industry stakeholders are unhappy with provisions in the House bill that differ from the recently passed Senate measure.

You may also be interested in...

Patent Bill Drama Moves To House As Senate Hands Brand Pharma Victory

With the Senate poised to approve its version of the patent reform bill, House Judiciary Committee Chairman Lamar Smith, R-Texas, will soon be in the driver's seat of a piece of legislation that could significantly alter the relationships pharmaceutical companies have with both their licensing partners and generic adversaries.

US FDA Pharmaceutical Quality Office Lauds Continuous Manufacturing Approvals

The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.

Warning Letter Roundup & Recap – 19 February 2020

No device-related warning letters were released by the US FDA the week of 19 February.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts